Chicago Partners Investment Group LLC Invests $316,000 in Cencora, Inc. $COR

Chicago Partners Investment Group LLC bought a new position in shares of Cencora, Inc. (NYSE:COR) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 1,078 shares of the company’s stock, valued at approximately $316,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Obermeyer Wealth Partners lifted its position in shares of Cencora by 1.3% during the first quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock worth $758,000 after purchasing an additional 36 shares during the last quarter. Grove Bank & Trust lifted its position in shares of Cencora by 4.3% during the second quarter. Grove Bank & Trust now owns 879 shares of the company’s stock worth $264,000 after purchasing an additional 36 shares during the last quarter. U.S. Capital Wealth Advisors LLC lifted its position in shares of Cencora by 0.4% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock worth $2,563,000 after purchasing an additional 38 shares during the last quarter. Monument Capital Management lifted its position in shares of Cencora by 2.4% during the second quarter. Monument Capital Management now owns 1,637 shares of the company’s stock worth $491,000 after purchasing an additional 38 shares during the last quarter. Finally, Cromwell Holdings LLC lifted its position in shares of Cencora by 9.5% during the first quarter. Cromwell Holdings LLC now owns 450 shares of the company’s stock worth $125,000 after purchasing an additional 39 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the sale, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the sale, the chief executive officer owned 37,940 shares in the company, valued at $12,398,792. The trade was a 11.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 41,544 shares of company stock worth $12,230,941 in the last 90 days. Insiders own 10.80% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on COR. Weiss Ratings restated a “buy (b)” rating on shares of Cencora in a report on Wednesday, October 8th. Mizuho lifted their price objective on Cencora from $316.00 to $334.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Wells Fargo & Company lifted their price objective on Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Finally, Jefferies Financial Group lifted their price objective on Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a report on Monday, June 30th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $324.91.

Cencora Price Performance

COR opened at $328.98 on Friday. The business’s 50-day moving average is $303.30 and its two-hundred day moving average is $294.47. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $331.94. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The firm has a market capitalization of $63.78 billion, a PE ratio of 33.85, a price-to-earnings-growth ratio of 1.55 and a beta of 0.63.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.21. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company had revenue of $80.66 billion for the quarter, compared to analyst estimates of $80.34 billion. During the same quarter in the previous year, the firm earned $3.34 earnings per share. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. Research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were paid a dividend of $0.55 per share. The ex-dividend date was Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is presently 22.63%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.